NEW YORK (GenomeWeb) – Cepheid said yesterday that it will delay the international market launch of its point-of-care platform, the Omni, by one year to the third quarter of 2017.
The firm's stock fell sharply on the news, down more than 19 percent on Nasdaq at mid-day trading following the announcement.
Cepheid first unveiled the Omni in July 2015, when it also announced plans to develop a line of more rapid tests, called Xpert Xpress.
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try 360Dx Premium now.
You may already have institutional access!
Check if I qualify.
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
